Patents by Inventor William Alexander Denny

William Alexander Denny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190169113
    Abstract: pa The present invention relates to ketamine derivatives of the formula (I), pharmaceutical compositions comprising them, and methods for treating pain comprising administering them, and their use in the manufacture of medicaments for treating pain. The present invention also relates to methods for anaesthetizing and methods for sedating a subject comprising administering ketamine derivatives of the formula (II).
    Type: Application
    Filed: February 6, 2019
    Publication date: June 6, 2019
    Inventors: James Wallace Sleigh, William Alexander Denny, Jiney Jose, Swarnalatha Akuratiya Gamage, Martyn Gregory Harvey, Logan James Voss
  • Patent number: 10239825
    Abstract: The present invention relates to ketamine derivatives of the formula (I), pharmaceutical compositions comprising them, and methods for treating pain comprising administering them, and their use in the manufacture of medicaments for treating pain. The present invention also relates to methods for anaesthetizing and methods for sedating a subject comprising administering ketamine derivatives of the formula (II).
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: March 26, 2019
    Assignee: Auckland Uniservices Limited
    Inventors: James Wallace Sleigh, William Alexander Denny, Jiney Jose, Swarnalatha Akuratiya Gamage, Martyn Gregory Harvey, Logan James Voss
  • Patent number: 9896443
    Abstract: Compounds of formula (1a) and pharmaceutically acceptable salts, solvates, and hydrates thereof and related methods of modulatin perforin activity on a cell: wherein Ring A is selected from a 6-10 membered aryl, 5-6 membered cycloalkyi, 5-6 membered heteroaryl or 5-6 membered heterocyclyl, wherein the heteroaryl and heterocyclyl rings comprise at least one heteroatom selected from N, O or S; and wherein the aryl, cycloalkyi, heteroaryl or heterocyclyl rings are optionally substituted with 1 to 3 substituents selected from halo, nitro, —C1-Cealkyl, —C1-Ceaminoalkyl, —C1-C6hydroxyalkyl, -haloC1-C6alkyl, —C1-C6alkoxyl, -haloC1—C<aIkoxyl, heteroaryl, aryl, hydroxyl, —C(0)Ci-C6alkyl, —OC(0)Ci-C6alkyl, —CH2OC(O)CrC6alkyl, —C(O)OC1, —C6alkyI, —NHC(O)C1, —C6alkyl, —NHS(O)2C1-C6alkyl, —S(O)2C1-C6alkyl, —S(O)2NH2, and —C(O)NJJ; Ring B is a 6-10 membered arylene or a 5-6 membered heteroarylene comprising at least one heteroatom selected from N, 0 or S; and wherein the aryl or heteroaryl is optionally, substituted wit
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: February 20, 2018
    Assignee: Peter MacCallum Cancer Institute
    Inventors: Julie Ann Spicer, William Alexander Denny, Christian Karl Miller, Patrick David O'Connor, Kristiina Huttunen, Joseph A. Trapani, Geoff Hill, Kylie Alexander
  • Publication number: 20170190653
    Abstract: The present invention relates to ketamine derivatives of the formula (I), pharmaceutical compositions comprising them, and methods for treating pain comprising administering them, and their use in the manufacture of medicaments for treating pain. The present invention also relates to methods for anaesthetizing and methods for sedating a subject comprising administering ketamine derivatives of the formula (II).
    Type: Application
    Filed: March 20, 2017
    Publication date: July 6, 2017
    Inventors: James Wallace Sleigh, William Alexander Denny, Jiney Jose, Swarnalatha Akuratiya Gamage, Martyn Gregory Harvey, Logan James Voss
  • Publication number: 20160031877
    Abstract: The invention provides kinase inhibitors of Formula I: wherein either: (1) R1 is H, and (a) R2 is (3-chlorobenzyl)oxy- and R3 is chloro; (b) R2 and R3, together with the carbon atoms to which they are attached, form 1-(3-fluorobenzyl)-1H-pyrazole; (c) R2 is 2-pyridinylmethoxy and R3 is chloro; (d) R2 and R3 are both chloro; (e) R2 is chloro and R3 is bromo; (f) R2 and R3 are both bromo; (g) R2 is fluoro and R3 is ethynyl; (h) R2 is chloro and R3 is ethynyl; (i) R2 is bromo and R3 is ethynyl; (j) other than when R2 is in the 3-position in combination with R3 in the 4-position, R2 is bromo and R3 is fluoro; (k) R2 is 2-pyridinylmethoxy and R3 is fluoro; or (l) R2 is 2-pyridinylmethoxy and R3 is bromo; or (2) at least one of R1, R2 and R3 is selected from benzyloxy, 3-chlorobenzyloxy and 2-pyridinylmethoxy and when at least one of R1, R2 and R3 is not benzyloxy, 3-chlorobenzyloxy or 2-pyridinylmethoxy, each of the others is independently selected from H, halogen, and C2-C4 alkynyl, with the proviso that
    Type: Application
    Filed: June 30, 2015
    Publication date: February 4, 2016
    Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Guo-Liang Lu, Ho Huat Lee, Amir Ashoorzadeh, Robert Forbes Anderson, William Robert Wilson, William Alexander Denny, Huai-Ling Hsu, Andrej Maroz, Stephen Michael Frazer Jamieson, Alexandra Marie Mowday, Kendall Marie Carlin
  • Publication number: 20160002222
    Abstract: The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I: where: X is any negatively charged counterion; R1 is a group of the formula —(CH2)nTr, where Tr is an aromatic nitroheterocyde or aromatic nitrocarbocycle and —(CH2)nTr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R2, R3 and R4 may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R2)(R3)(R4)N, or two of R2, R3, and R4 may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R2, R3, and R4 may be absent and two of R2, R3 and R4 form an aromatic heterocyclic amine ring of a kinase inhibitor. The compounds of the invention are useful in treating proliferative diseases such as cancer.
    Type: Application
    Filed: June 4, 2015
    Publication date: January 7, 2016
    Inventors: Jeffrey Bruce Smaill, ADAM VORN PATTERSON, MICHAEL PATRICK HAY, WILLIAM ALEXANDER DENNY, WILLIAM ROBERT WILSON, GUO-LIANG LU, ROBERT FORBES ANDERSON, HO HUAT LEE, AMIR ASHOORZADEH
  • Patent number: 9198913
    Abstract: The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: December 1, 2015
    Assignee: Global Alliance for TB Drug Development
    Inventors: William Alexander Denny, Andrew Mark Thompson, Adrian Blaser, Zhenkun Ma, Brian Desmond Palmer, Hamish Scott Sutherland, Iveta Kmentova
  • Publication number: 20150259277
    Abstract: The present invention relates to ketamine derivatives of the formula (I), pharmaceutical compositions comprising them, and methods for treating pain comprising administering them, and their use in the manufacture of medicaments for treating pain. The present invention also relates to methods for anaesthetizing and methods for sedating a subject comprising administering ketamine derivatives of the formula (II).
    Type: Application
    Filed: October 8, 2013
    Publication date: September 17, 2015
    Inventors: James Wallace Sleigh, William Alexander Denny, Jiney Jose, Swarnalatha Akuratiya Gamage, Martyn Gregory Harvey, Logan James Voss
  • Patent number: 9101632
    Abstract: The invention provides kinase inhibitors of Formula I: wherein either: (1) R1 is H, and (a) R2 is (3-chlorobenzyl)oxy-and R3 is chloro; (b) R2 and R3, together with the carbon atoms to which they are attached, form 1-(3-fluorobenzyl)-1H-pyrazole; (c) R2 is 2-pyridinylmethoxy and R3 is chloro; (d) R2 and R3 are both chloro; (e) R2 is chloro and R1 is bromo; (f) R2 and R3 are both bromo; (g) R2 is fluoro and R3 is ethynyl; (h) R2 is chloro and R3 is ethynyl; (i) R2 is bromo and R3 is ethynyl; (j) other than when R1 is in the 3-position in combination with R3, in the 4-position, R2 is bromo and R3 is fluoro; (k) R2 is 2-pyridinylmethoxy and R3 is fluoro; or (l) R2 is 2-pyridinylmethoxy and R1 is bromo; or (2) at least one of R1, R2 and R3 is selected from benzyloxy, 3-chlorobenzyloxy and 2-pyridinylmethoxy and when at least one of R1, R2 and R3 is not benzyloxy, 3-chlorobenzyloxy or 2-pyridinylmethoxy, each of the others is independently selected from H, halogen, and C2-C4 alkynyl, with the proviso that
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: August 11, 2015
    Assignee: AUCKLAND UNISERVICES LIMITED
    Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Guo-Liang Lu, Ho Huat Lee, Amir Ashoorzadeh, Robert Forbes Anderson, William Robert Wilson, William Alexander Denny, Huai-Ling Annie Hsu, Andrej Maroz, Stephen Michael Frazer Jamieson, Alexandra Marie Mowday, Kendall Marie Carlin
  • Publication number: 20150218150
    Abstract: Compounds of formula (1a) and pharmaceutically acceptable salts, solvates, and hydrates thereof and related methods of modulatin perforin activity on a cell: wherein Ring A is selected from a 6-10 membered aryl, 5-6 membered cycloalkyi, 5-6 membered heteroaryl or 5-6 membered heterocyclyl, wherein the heteroaryl and heterocyclyl rings comprise at least one heteroatom selected from N, O or S; and wherein the aryl, cycloalkyi, heteroaryl or heterocyclyl rings are optionally substituted with 1 to 3 substituents selected from halo, nitro, —C1-Cealkyl, —C1-Ceaminoalkyl, —C1-C6hydroxyalkyl, -haloC1-C6alkyl, —C1-C6alkoxyl, -haloC1—C<aIkoxyl, heteroaryl, aryl, hydroxyl, —C(0)Ci-C6alkyl, —OC(0)Ci-C6alkyl, —CH2OC(O)CrC6alkyl, —C(O)OC1, —C6alkyI, —NHC(O)C1, —C6alkyl, —NHS(O)2C1-C6alkyl, —S(O)2C1-C6alkyl, —S(O)2NH2, and —C(O)NJJ; Ring B is a 6-10 membered arylene or a 5-6 membered heteroarylene comprising at least one heteroatom selected from N, 0 or S; and wherein the aryl or heteroaryl is optionally, substituted wit
    Type: Application
    Filed: August 21, 2013
    Publication date: August 6, 2015
    Inventors: Julie Ann Spicer, William Alexander Denny, Christian Karl Miller, Patrick David O'Connor, Kristiina Huttunen, Joseph A. Trapani, Geoff Hill, Kylie Alexander
  • Patent number: 9073916
    Abstract: The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I: where: X is any negatively charged counterion; R1 is a group of the formula —(CH2)nTr, where Tr is an aromatic nitroheterocycle or aromatic nitrocarbocycle and —(CH2)nTr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R2, R3 and R4 may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R2)(R3)(R4)N, or two of R2, R3, and R4 may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R2, R3 and R4 may be absent and two of R2, R3 and R4 form an aromatic heterocyclic amine ring of a kinase inhibitor. The compounds of the invention are useful in treating proliferative diseases such as cancer.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: July 7, 2015
    Assignee: AUCKLAND UNISERVICES LIMITED
    Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Michael Patrick Hay, William Alexander Denny, William Robert Wilson, Guo-Liang Lu, Robert Forbes Anderson, Ho Huat Lee, Amir Ashoorzadeh
  • Publication number: 20130065897
    Abstract: The present invention provides novel compounds of the Formula I, pharmaceutical compositions comprising such compounds and methods for using such compounds as agents or drugs for inhibiting perforin activity and for treating a subject at risk of or susceptible to a disease or disorder, or having a disease or disorder associated with undesirable perforin activity.
    Type: Application
    Filed: December 22, 2010
    Publication date: March 14, 2013
    Applicant: PETER MACCALLUM CANCER INSTITUTE
    Inventors: Julie Ann Spicer, Kristiina Maria Huttunen, Dani Michelle Lyons, Joseph Albert Trapani, Mark John Smyth, William Alexander Denny
  • Patent number: 8293734
    Abstract: The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: October 23, 2012
    Assignee: Global Alliance for TB Drug Development
    Inventors: Andrew Mark Thompson, William Alexander Denny, Adrian Blaser, Zhenkun Ma
  • Publication number: 20120225862
    Abstract: Provided are certain heteroaryl benzamides, compositions, and methods of their manufacture and use.
    Type: Application
    Filed: July 21, 2010
    Publication date: September 6, 2012
    Applicants: AUCKLAND UNIVSERVICES LIMITED, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Patrick D. Sutphin, Denise A. Chan, Sandra Turcotte, William Alexander Denny, Michael Patrick Hay, Anna Claire Giddens, Muriel Marie Bonnet, Amato J. Giaccia
  • Publication number: 20120202832
    Abstract: The invention provides kinase inhibitors of Formula I: wherein either: (1) R1 is H, and (a) R2 is (3-chlorobenzyl)oxy- and R3 is chloro; (b) R2 and R3, together with the carbon atoms to which they are attached, form 1-(3-fluorobenzyl)-1H-pyrazole; (c) R2 is 2-pyridinylmethoxy and R3 is chloro; (d) R2 and R3 are both chloro; (e) R2 is chloro and R1 is bromo; (f) R2 and R3 are both bromo; (g) R2 is fluoro and R3 is ethynyl; (h) R2 is chloro and R3 is ethynyl; (i) R2 is bromo and R3 is ethynyl; (j) other than when R1 is in the 3-position in combination with R3, in the 4-position, R2 is bromo and R3 is fluoro; (k) R2 is 2-pyridinylmethoxy and R3 is fluoro; or (l) R2 is 2-pyridinylmethoxy and R1 is bromo; or (2) at least one of R1, R2 and R3 is selected from benzyloxy, 3-chlorobenzyloxy and 2-pyridinylmethoxy and when at least one of R1, R2 and R3 is not benzyloxy, 3-chlorobenzyloxy or 2-pyridinylmethoxy, each of the others is independently selected from H, halogen, and C2-C4 alkynyl, with the proviso tha
    Type: Application
    Filed: September 2, 2010
    Publication date: August 9, 2012
    Applicant: Auckland Uniservices Limited
    Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Guo-Liang Lu, Ho Huat Lee, Amir Ashoorzadeh, Robert Forbes Anderson, William Robert Wilson, William Alexander Denny, Huai-Ling (Annie) Hsu, Andrej Maroz, Stephen Michael Frazer Jamieson, Alexandra Marie Mowday, Kendall Marie Carlin
  • Publication number: 20120077811
    Abstract: The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I: where: X is any negatively charged counterion; R1 is a group of the formula —(CH2)nTr, where Tr is an aromatic nitroheterocycle or aromatic nitrocarbocycle and —(CH2)nTr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R2, R3 and R4 may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R2)(R3)(R4)N, or two of R2, R3, and R4 may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R2, R3 and R4 may be absent and two of R2, R3 and R4 form an aromatic heterocyclic amine ring of a kinase inhibitor. The compounds of the invention are useful in treating proliferative diseases such as cancer.
    Type: Application
    Filed: March 11, 2010
    Publication date: March 29, 2012
    Inventors: Jeffrey Bruce Smaill, Adam Vorn Patterson, Michael Patrick Hay, William Alexander Denny, William Robert Wilson, Guo-Liang Lu, Robert Forbes Anderson, Ho Huat Lee, Amir Ashoorzadeh
  • Publication number: 20120028973
    Abstract: The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Application
    Filed: July 30, 2010
    Publication date: February 2, 2012
    Applicant: Global Alliance for TB Drug Development
    Inventors: William Alexander Denny, Andrew Mark Thompson, Adrian Blaser, Brian Desmond Palmer, Zhenkun Ma, Hamish Scott Sutherland, Iveta Kmentova
  • Patent number: 7989451
    Abstract: The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: August 2, 2011
    Assignee: Auckland Uniservices Limited
    Inventors: Michael Patrick Hay, Adrian Blaser, William Alexander Denny, Kevin Owen Hicks, Ho Huat Lee, Karin Pchalek, Frederik Bastiaan Pruijn, Bronwyn Gae Siim, William Robert Wilson, Shangjin Yang
  • Publication number: 20110053907
    Abstract: Provided herein are substituted pyrimidine and triazine derivatives, including bicyclic pyrimidine derivatives, their pharmaceutical compositions, their preparation, and their use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs. In one embodiment, the pyrimidine and triazine derivatives are morpholino-pyrimidine, morpholino-triazine, pyridyl-pyrimidine, and pyridyl-triazine derivatives which are selective irreversible inhibitors of the p110? isoform of PI3K.
    Type: Application
    Filed: March 26, 2009
    Publication date: March 3, 2011
    Applicant: Auckland UniServices Limited
    Inventors: Gordon William Rewcastle, Peter Robin Shepherd, Glaire Chaussade, William Alexander Denny, Swarnalatha Akuratiya Gamage
  • Publication number: 20110028466
    Abstract: The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.
    Type: Application
    Filed: July 30, 2010
    Publication date: February 3, 2011
    Applicant: Global Alliance for TB Drug Development
    Inventors: Andrew Mark Thompson, William Alexander Denny, Adrian Blaser, Zhenkun Ma